ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

http://oncologypro.esmo.org/Meeting-Resourc...-with-cell-invasiveness-in-pancreatic-cancer

Pancreatic cancer is highly aggressive cancer with early metastasis, and most patients developed metastasis within 1 year after curative surgery. However there is little study to identify the mechanism of metastasis in pancreatic cancer.

Date: 28 Jun 2017
Presenter: Jin Niang Nan
Resources: Abstract
Topics: Gastrointestinal Cancers, Pancreatic Cancer

http://oncologypro.esmo.org/Meeting-Resourc...monocyte-ratio-in-colorectal-cancer-patients

The aim of our study was to evaluate the prognostic value of lymphocyte-to-monocyte ratio (LMR) and serum CEA in colorectal cancer patients qualified to surgery.

Date: 28 Jun 2017
Presenter: Ewa Wojcik
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ancer-2017/Epidemiology-of-pancreatic-cancer

With a dramatic increase of incidence and a very poor prognosis, the treatment of pancreatic cancer remains a challenge. Unfortunately, the majority of cases are diagnosed at an advanced stage, where...

Date: 28 Jun 2017
Presenter: Nacera Caid
Resources: Abstract
Topics: Gastrointestinal Cancers, Pancreatic Cancer

http://oncologypro.esmo.org/Meeting-Resourc...dedness-in-colorectal-cancer-CC-patients-pts

Right-sided colon cancer (RCC) and left-sided colorectal cancer (LCRC) have a different biology and genomic pattern. Primary tumor location is emerging as an important prognostic factor in metastatic CC patients eligible to target therapy.

Date: 28 Jun 2017
Presenter: Vincenzo Ricci
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...midine-based-dCRT-A-single-centre-experience

The CROSS trial has established CP based CRT as standard of care in pre-operative treatment of oesophageal cancer, and this regimen is being increasingly used as a component of dCRT for inoperable eosphageal cancer.

Date: 28 Jun 2017
Presenter: Nicola Warner
Resources: Abstract
Topics: Gastrointestinal Cancers, Oesophageal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-colorectal-cancer-mCRC-A-case-control-study

Almost half of RAS and BRAF wt mCRC patients do not respond to anti-EGFRs. Different molecular alterations suggested as predictors of primary resistance have not been validated.

Date: 28 Jun 2017
Presenter: Chiara Cremolini
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...therapy-Is-it-an-important-prognostic-factor

Locally advanced esophageal cancers are generally treated with neoadjuvant chemoradiotherapy, followed by surgery in operable candidates. However, even if a patient is diagnosed with operable disease,...

Date: 28 Jun 2017
Presenter: Hyung Kang Sun
Resources: Abstract
Topics: Gastrointestinal Cancers, Oesophageal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...emozolomide-using-proteomic-analysis-of-MGMT

Temozolomide (TMZ) is a standard treatment for melanoma and glioblastoma and it has shown limited but encouraging activity in patients with metastatic colorectal cancer (mCRC).

Date: 28 Jun 2017
Presenter: Fabiola Cecchi
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...al-of-patients-with-locally-advanced-disease

In the time of diagnosis esophageal carcinoma is still locally advanced disease for majority of patients. Different treatment modalities were tried, however, it is remained disease with poor prognosis and median survival less than 10 months.

Date: 28 Jun 2017
Presenter: Ingrid Zavacka
Resources: Abstract
Topics: Gastrointestinal Cancers, Oesophageal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...n-survival-ERCC1-and-TOPO1-adjusted-analysis

The choice between Irinotecan and Oxaliplatin-based chemotherapy as first-line treatment in metastatic colo-rectal patients is a difficult task. No specific criteria, guidelines or recommendation were defined.

Date: 28 Jun 2017
Presenter: Andreea Serban
Resources: Abstract
Topics: Gastrointestinal Cancers, Rectal Cancer